All
Immunotherapy Regimen Granted Priority Review in Small Cell Lung Cancer
December 5th 2018The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) for use in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Lynparza Significantly Delays Progression in Advanced Ovarian Cancer, Study Finds
December 4th 2018Maintenance treatment with Lynparza (olaparib) after chemotherapy has been found to significantly extend progression-free survival in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation, according to a recent phase 3 study.
FDA Approves Xospata and Companion Diagnostic Test for Leukemia Treatment
November 29th 2018The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.
Immunotherapy May Mean No Chemotherapy for Some With Metastatic Head and Neck Cancer
November 27th 2018Immunotherapy may lead to a major change in how the treatment of metastatic recurrent head and neck cancer is approached, according to Barbara Burtness, M.D., a professor of medicine at Yale School of Medicine.